The Associated Press
July 14, 2010, 4:26PM ET
Mylan gets FDA approval for generic arthritis drug
PITTSBURGH
Mylan Inc. said Wednesday the Food and Drug Administration approved its generic version of the osteoarthritis and rheumatoid arthritis drug Nabumetone.
The FDA approval allows Mylan to sell 500 milligram and 750 milligram tablets of Nabumetone. It is a nonsteroidal anti-inflammatory drug, which is a popular type of arthritis and inflammation treatment.
Several generic versions of Nabumetone are already on the market under brand names including Relifex and Relafen.
Mylan stock closed trading unchanged at $17.85.
Most Popular Stories
- Three Types of People to Fire Immediately
- Lego Is for Girls
- Google's Spreading Tentacles of Influence
- Gatorade Goes Back to the Lab
- Impress Potential Investors in 12 Steps
- Three Types of People to Fire Immediately
- Which Is America's Best City?
- Lego Is for Girls
- Top B-School Stories of 2011
- Professional Women and a Secure Retirement
